|
Oct 1
|
55-Year-Old Who Reached $3,900 Per Month Income In Just 5 Years Shares Portfolio: Top 9 Stocks And ETFs
|
|
Oct 1
|
J&J to invest over $2 billion for new manufacturing facility in North Carolina
|
|
Oct 1
|
Johnson & Johnson (NYSE:JNJ) is a favorite amongst institutional investors who own 73%
|
|
Oct 1
|
Johnson & Johnson launches TECNIS Odyssey intraocular lens in US
|
|
Oct 1
|
J&J drops 340B rebate plan following government pressure
|
|
Sep 30
|
J&J Backtracks on Plan Aimed at Hospital Drug-Discount Program
|
|
Sep 30
|
Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
|
|
Sep 30
|
J&J clinches EC approval for first single-pill PAH combo
|
|
Sep 30
|
80 Hedge Funds Hold Stakes in Johnson & Johnson (JNJ) as of Q2 2024
|
|
Sep 30
|
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
|
|
Sep 30
|
Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial
|
|
Sep 30
|
15 Best Dividend Stocks for Lifelong Passive Income
|
|
Sep 30
|
Johnson & Johnson (JNJ): Hedge Funds Bet Big on Healthcare Giant Amid 4.3% Q2 Revenue Increase
|
|
Sep 28
|
Johnson & Johnson announces updated results from Phase 1b RedirecTT-1 study
|
|
Sep 28
|
Johnson & Johnson provides updated results from Phase 1b TRIMM-2 study
|
|
Sep 28
|
2 Excellent Dividend Stocks to Buy With Less Than $200
|
|
Sep 27
|
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
|
|
Sep 27
|
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
|
|
Sep 27
|
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
|
|
Sep 27
|
DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
|